Alexander Bujotzek
Alexander Bujotzek
Roche Innovation Center Munich
Verified email at
Cited by
Cited by
Five computational developability guidelines for therapeutic antibody profiling
MIJ Raybould, C Marks, K Krawczyk, B Taddese, J Nowak, AP Lewis, ...
Proceedings of the National Academy of Sciences 116 (10), 4025-4030, 2019
Thera-SAbDab: the therapeutic structural antibody database
MIJ Raybould, C Marks, AP Lewis, J Shi, A Bujotzek, B Taddese, ...
Nucleic acids research 48 (D1), D383-D388, 2020
Thera-SAbDab: the therapeutic structural antibody database
MIJ Raybould, C Marks, AP Lewis, J Shi, A Bujotzek, B Taddese, ...
Nucleic acids research 48 (D1), D383-D388, 2020
DNA-programmed spatial screening of carbohydrate–lectin interactions
C Scheibe, A Bujotzek, J Dernedde, M Weber, O Seitz
Chemical science 2 (4), 770-775, 2011
ABlooper: fast accurate antibody CDR loop structure prediction with accuracy estimation
B Abanades, G Georges, A Bujotzek, CM Deane
Bioinformatics 38 (7), 1877-1880, 2022
Brain shuttle antibody for Alzheimer’s disease with attenuated peripheral effector function due to an inverted binding mode
F Weber, B Bohrmann, J Niewoehner, JAA Fischer, P Rueger, ...
Cell reports 22 (1), 149-162, 2018
DNA‐controlled bivalent presentation of ligands for the estrogen receptor
F Abendroth, A Bujotzek, M Shan, R Haag, M Weber, O Seitz
Angewandte Chemie International Edition 50 (37), 8592-8596, 2011
Quantifying the rebinding effect in multivalent chemical ligand-receptor systems
M Weber, A Bujotzek, R Haag
The Journal of chemical physics 137 (5), 2012
Characterization of the pathoimmunology of necrotizing enterocolitis reveals novel therapeutic opportunities
SX Cho, I Rudloff, JC Lao, MA Pang, R Goldberg, CB Bui, CA McLean, ...
Nature communications 11 (1), 5794, 2020
Prediction of VH–VL domain orientation for antibody variable domain modeling
A Bujotzek, J Dunbar, F Lipsmeier, W Schšfer, I Antes, CM Deane, ...
Proteins: Structure, Function, and Bioinformatics 83 (4), 681-695, 2015
ImmuneBuilder: Deep-Learning models for predicting the structures of immune proteins
B Abanades, WK Wong, F Boyles, G Georges, A Bujotzek, CM Deane
Communications Biology 6 (1), 575, 2023
Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody
C Augsberger, G Hšnel, W Xu, V Pulko, LJ Hanisch, A Augustin, J Challier, ...
Blood, The Journal of the American Society of Hematology 138 (25), 2655-2669, 2021
Antibodies exhibit multiple paratope states influencing VH–VL domain orientations
ML FernŠndez-Quintero, ND Pomarici, BA Math, KB Kroell, F Waibl, ...
Communications biology 3 (1), 589, 2020
VH-VL orientation prediction for antibody humanization candidate selection: A case study
A Bujotzek, F Lipsmeier, SF Harris, J Benz, A Kuglstatter, G Georges
MAbs 8 (2), 288-305, 2016
Ab-Ligity: identifying sequence-dissimilar antibodies that bind to the same epitope
WK Wong, SA Robinson, A Bujotzek, G Georges, AP Lewis, J Shi, ...
MAbs 13 (1), 1873478, 2021
VH‐VL interdomain dynamics observed by computer simulations and NMR
ML FernŠndez‐Quintero, VJ Hoerschinger, LM Lamp, A Bujotzek, ...
Proteins: Structure, Function, and Bioinformatics 88 (7), 830-839, 2020
Conformational analysis of bivalent estrogen receptor ligands: from intramolecular to intermolecular binding
M Shan, A Bujotzek, F Abendroth, A Wellner, R Gust, O Seitz, M Weber, ...
ChemBioChem 12 (17), 2587-2598, 2011
Nonsteroidal bivalent estrogen ligands: an application of the bivalent concept to the estrogen receptor
M Shan, KE Carlson, A Bujotzek, A Wellner, R Gust, M Weber, ...
ACS chemical biology 8 (4), 707-715, 2013
MoFvAb: modeling the Fv region of antibodies
A Bujotzek, A Fuchs, C Qu, J Benz, S Klostermann, I Antes, G Georges
MAbs 7 (5), 838-852, 2015
Hapten-directed spontaneous disulfide shuffling: a universal technology for site-directed covalent coupling of payloads to antibodies
S Dengl, E Hoffmann, M Grote, C Wagner, O Mundigl, G Georges, ...
The FASEB Journal 29 (5), 1763, 2015
The system can't perform the operation now. Try again later.
Articles 1–20